S.Biomedics Co., Ltd. (KOSDAQ:304360)
South Korea flag South Korea · Delayed Price · Currency is KRW
21,500
-400 (-1.83%)
At close: Sep 9, 2026

S.Biomedics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-12,058-8,122-6,691-10,321-6,327-5,667
Depreciation & Amortization
2,4132,0431,7251,5531,5171,448
Loss (Gain) From Sale of Assets
0---5.49--
Loss (Gain) From Sale of Investments
-24.15-105.87-25.23-51.81-6.77-0.24
Stock-Based Compensation
514.67442.3555.3886.21148.08217.39
Provision & Write-off of Bad Debts
6.94272.8412.67174.99-160.05-188.31
Other Operating Activities
873.73482.881,8564,5643,1051,666
Change in Accounts Receivable
81.3-155.49201.51-771.8-697.48440.6
Change in Inventory
10.15462.0271.14-830.05-817.71-204.21
Change in Accounts Payable
359.44190.22-292.7363.31379.86-423.02
Change in Other Net Operating Assets
710.28509.85-413.31-610.69-347.05-576.36
Operating Cash Flow
-7,113-3,981-3,500-6,149-3,205-3,287
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-4,035-4,604-1,390-1,847-9,295-474.49
Sale of Property, Plant & Equipment
---22.14--
Sale (Purchase) of Intangibles
-175-15-324.4--149.39-15.8
Investment in Securities
7,49610,582-8,547-6,6552,708-3,445
Other Investing Activities
102.03-563.05-86-343.25-43.69-64.87
Investing Cash Flow
3,3885,400-10,348-8,824-6,871-3,990

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-6,30011,775-7,0004,860
Total Debt Issued
28,2786,30011,775-7,0004,860
Long-Term Debt Repaid
--7,780-2,573-1,156-732.69-1,061
Total Debt Repaid
-8,085-7,780-2,573-1,156-732.69-1,061
Net Debt Issued (Repaid)
20,193-1,4809,202-1,1566,2673,799
Issuance of Common Stock
18,5171,6537,57414,282--
Other Financing Activities
-0-0133.5-808.56852.9362.18
Financing Cash Flow
38,710173.3916,90912,3188,0204,161

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
28.598.3411.89-0.86-9.4759.35
Net Cash Flow
35,0141,6013,074-2,656-2,066-3,057

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-11,148-8,584-4,890-7,996-12,501-3,762
Free Cash Flow Growth
------
Free Cash Flow Margin
-67.59%-51.88%-35.61%-61.00%-103.20%-42.42%
Free Cash Flow Per Share
-917.42-722.99-425.15-731.44-1223.19-370.56
Levered Free Cash Flow
-9,980-3,508-4,647-8,051-9,322-3,057
Unlevered Free Cash Flow
-9,073-2,602-4,150-7,499-8,867-2,636

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
390.75363.82426.59487.05156.16158.4
Cash Income Tax Paid
239.77176.067831.473.22-20.09
Change in Working Capital
1,1611,007-433.4-2,149-1,482-762.99